Home
About
Overview
Sharing Data
ORCID
Help
History (1)
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014 May 08; 370(19):1809-19.
View in:
PubMed
subject areas
Adult
Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Azetidines
Cholesterol, LDL
Combined Modality Therapy
Double-Blind Method
Ezetimibe
Female
Heptanoic Acids
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hyperlipidemias
Least-Squares Analysis
Male
Middle Aged
Proprotein Convertase 9
Proprotein Convertases
Pyrroles
Serine Endopeptidases